CP91110P: A Computationally Designed Multi-Epitope Vaccine Candidate for Tuberculosis via TLR-2/4 Synergistic...

Area of Science:

• Computational vaccinology
• Bioinformatics
• Immunoinformatics

Background:

• Tuberculosis (TB) remains a critical global health challenge.
• Current vaccines like BCG have limitations against latent and drug-resistant TB.
• Novel vaccine strategies are essential for effective TB control.

Purpose of the Study:

• To design and computationally evaluate a multi-epitope vaccine (MEV) for tuberculosis.
• To assess the MEV's immunogenicity, structural stability, and receptor interactions.
• To predict the MEV's potential efficacy and population coverage.

Main Methods:

• Bioinformatics tools for epitope selection and MEV design.
• Disulfide engineering for structural stability optimization.
• Molecular docking and dynamics simulations for receptor binding analysis.
• Computational assessment of antigenicity, immunogenicity, and population coverage.

Main Results:

• The designed MEV, CP91110P, demonstrated high predicted global HLA coverage (86.18%).
• CP91110P exhibited high antigenicity and immunogenicity with favorable stability and solubility.
• Stable binding to TLR-2 and flexible interaction with TLR-4 were predicted, suggesting potential for robust immune responses.

Conclusions:

• CP91110P is a computationally validated candidate for a novel tuberculosis vaccine.
• The MEV shows potential for stable TLR-2 binding and flexible TLR-4 interaction.
• Further experimental validation is recommended to confirm its efficacy in tuberculosis prevention.